Rezolute, Inc. Form 10-K Summary
Business context and reporting period
Rezolute is a clinical-stage rare-disease biotechnology company developing ersodetug, an investigational monoclonal antibody intended to treat refractory hypoglycemia associated with congenital and tumor hyperinsulinism. The report covers the fiscal year ended June 30, 2026, and was filed September 24, 2026. The company has no approved commercial products and has not generated meaningful revenue.
- Lead programs: sunRIZE Phase 3 in congenital hyperinsulinism and upLIFT Phase 3 in tumor hyperinsulinism.
- Employees: 58 full-time employees as of June 30, 2026; 63 as of September 21, 2026.
- Stock: Nasdaq-listed common stock under ticker RZLT; 96.4 million shares outstanding at June 30, 2026 and 96.7 million as of September 21, 2026.
Financial performance and liquidity
| Metric | FY 2026 | FY 2025 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $53.8 million | $61.5 million | Down 13% |
| General and administrative expense | $29.2 million | $18.4 million | Up 59% |
| Total operating expenses | $83.0 million | $79.9 million | Up 4% |
| Interest and other income, net | $5.4 million | $5.5 million | Down 2% |
| Net loss | $77.6 million | $74.4 million | Loss increased 4% |
| Basic and diluted loss per share | $0.75 | $0.98 | Loss per share improved |
| Cash used in operating activities | $64.6 million | $69.1 million | Use decreased $4.4 million |
R&D declined primarily because of lower ersodetug manufacturing and milestone costs, partially offset by higher employee compensation, clinical start-up costs, and severance. G&A increased due to higher compensation, share-based compensation, business development, commercial planning, market research, and severance costs. Share-based compensation expense increased to $14.5 million from $7.1 million.
| Balance-sheet and liquidity item | June 30, 2026 | June 30, 2025 |
|---|---|---|
| Cash and cash equivalents | $10.6 million | $94.1 million |
| Marketable debt securities | $97.2 million | $73.8 million |
| Total capital resources | $107.8 million | $167.9 million |
| Working capital | $99.1 million | Not clearly provided in the filing text |
| Total liabilities | $12.2 million | $13.4 million |
| Accumulated deficit | $481.4 million | $403.9 million |
Management believes cash, cash equivalents, and marketable debt securities are sufficient to fund planned activities and contractual obligations for at least 12 months from the financial-statement issuance date. All $97.2 million of marketable debt securities were scheduled to mature within the 12 months ending June 30, 2027. The company expects to require additional equity or debt financing to fund longer-term requirements.
Net cash used in investing activities was $21.1 million, primarily reflecting purchases of marketable debt securities. Net cash provided by financing activities was $2.2 million, primarily from employee stock-option exercises, compared with $107.3 million in FY 2025 from equity offerings and related financings. The company had no conventional debt outstanding at June 30, 2026, but recorded a $0.5 million embedded derivative liability related to a legacy exit-fee agreement.
Material changes versus the prior comparable period
- The sunRIZE congenital HI Phase 3 study, announced in December 2025, failed to meet its primary endpoint and key secondary endpoint at the defined Week 24 evaluation window.
- Management reported favorable trends across multiple CGM-based and post-hoc measures, but these analyses were not the prespecified primary or key secondary endpoints and remain subject to regulatory interpretation.
- The company reduced its workforce by 29 employees in December 2025 and recorded $1.5 million of severance expense, fully paid by January 2026.
- R&D spending fell $7.7 million, while G&A spending rose $10.8 million, resulting in a $3.1 million increase in operating loss.
- Cash and cash equivalents declined substantially as operating and investing cash uses exceeded current-period financing proceeds; total capital resources declined by approximately $60.1 million.
- Outstanding pre-funded warrants declined from 16.4 million shares to 8.2 million shares through cashless exercises, while common shares outstanding increased from 87.0 million to 96.4 million.
- In July 2026, XOMA, the original ersodetug licensor, was acquired by Ligand Pharmaceuticals; future licensing obligations now run to Ligand.
Clinical outlook, management commentary, and risks
Congenital HI: The FDA met with Rezolute on March 17, 2026 and requested comprehensive analysis datasets and summary outcomes for independent review. As of September 2026, the FDA was still evaluating a potential regulatory path forward, with no specific timeline for feedback. The company may need additional information or a new randomized study before submitting a marketing application. The sunRIZE open-label extension remained ongoing, with 56 participants still receiving ersodetug as of the filing; management reported continued glycemic benefit and reduced background standard-of-care therapy, but these observations are preliminary.
Tumor HI: The upLIFT Phase 3 study is a single-arm, open-label trial expected to enroll approximately 16 participants. Management expects to complete enrollment and announce topline results before the end of calendar 2026. Of the first eight participants, seven met the primary responder criterion; one participant withdrew while transitioning to hospice and is counted as a non-responder. Interim results are preliminary and may change after completion, verification, and regulatory review.
Potential regulatory filing: Assuming supportive upLIFT data and a favorable regulatory path, management stated that it intends to submit a BLA for ersodetug in mid-2027. This is not assured and depends on clinical results, FDA feedback, manufacturing readiness, and available financing.
- The company has a history of substantial losses, no meaningful revenue, and an accumulated deficit of $481.4 million.
- Additional financing will likely be required; financing may dilute existing shareholders or impose restrictive terms.
- Clinical results may fail to demonstrate efficacy, and preliminary or interim data may differ materially from final results.
- FDA may require additional studies for congenital HI or determine that current data are insufficient for approval.
- UpLIFT’s modified, single-arm design may not establish efficacy, despite encouraging interim data.
- Regulatory approval would trigger a $25.0 million ersodetug milestone payment. Additional potential ersodetug milestones total up to $185.0 million, plus royalties based on net sales.
- ActiveSite obligations include up to $42.5 million in additional clinical, regulatory, sales, and alternative-indication milestones, including a $5.0 million payment upon dosing the first patient in an RZ402 Phase 3 study, plus 2% royalties on applicable net sales.
- Clinical development depends substantially on third-party contract research organizations, manufacturers, and suppliers.
- Marketable debt securities carry interest-rate, credit, concentration, and liquidity risks; $55.4 million was invested in issuers in the banking and financial-services industries at June 30, 2026.
- Law firms announced investigations concerning alleged securities-law violations following the sunRIZE results, but the company reported no pending or threatened lawsuit expected to have a material effect as of June 30, 2026.
- Federal net operating loss carryforwards totaled approximately $248.9 million, but $33.4 million is expected to expire unused and the remaining amount is subject to Section 382 limitations.
Important facts for investors to verify
- Obtain the FDA’s eventual written feedback and determine whether a congenital HI BLA can be supported without a new randomized study.
- Verify final, audited upLIFT enrollment, responder results, safety data, and topline-to-final-data reconciliation.
- Assess the company’s cash runway after incorporating clinical costs, regulatory activities, licensing milestones, and potential manufacturing expenditures.
- Review the timing and financing implications of the possible $25.0 million regulatory approval milestone and other contingent license payments.
- Reconcile common shares, pre-funded warrants, stock options, RSUs, and other potential dilution to fully diluted share count.
- Monitor any securities litigation or claims arising from the sunRIZE trial outcome.
- Confirm the composition, maturities, credit quality, and unrealized losses of the marketable debt securities portfolio.
- Evaluate whether the reported CGM and open-label-extension observations are sufficient to overcome the failure of the sunRIZE prespecified endpoints under FDA standards.